We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Continuous Flow of Breakthroughs for Vapourtec

Continuous Flow of Breakthroughs for Vapourtec

Continuous Flow of Breakthroughs for Vapourtec

Continuous Flow of Breakthroughs for Vapourtec

Read time:

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Continuous Flow of Breakthroughs for Vapourtec"

First Name*
Last Name*
Email Address*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

By way of a comparison Vapourtec's two closest competitors in flow chemistry technology have been mentioned in 51 and 40 publications, respectively.

Recent published breakthroughs using Vapourtec’s pioneering E-Series system include the Continuous Synthesis of Organozinc Halides Coupled to Negishi Reactions¹ (Advanced Synthesis and Catalysis), Continuous flow-processing of organometallic reagents using an advanced peristaltic pumping system and the telescoped flow synthesis of (E/Z)-tamoxifen² (Organic Process Research and Development) and Continuous Flow Magnesiation of Functionalized Heterocycles and Acrylates with the Knochel-Hauser base (TMPMgCl⋅LiCl)³ (Angewandte Chemie International Edition).

Vapourtec founder and MD Duncan Guthrie commented: “The real world applications of continuous flow chemistry continue to grow with an ever increasing number of research breakthroughs and it is humbling to know that our technologies are playing their part in this progress.

“It’s a very exciting time to be involved in flow chemistry with positive implications for the pharma, industrial and education sectors and we are very pleased to see our systems operating at the cutting edge of research in laboratories across the world,” added Duncan.

Vapourtec design and manufacture flow chemistry systems for a wide variety of sectors across the globe including education, pharmaceutical and industry with their technologies used by all of the major pharmaceutical brands.

Established in 2003, Vapourtec has developed a flourishing international market for its technology with sales across much of the world including USA, China, Japan, Singapore and India. 

Vapourtec’s current list of publications can be found here 

¹Research carried out by the Department of Chemistry and Biochemistry at Florida State University (USA) in conjunction with Janssen Research and Development (Toledo, Spain) and the Facultad de Química (Universidad de Castilla-La Mancha, Spain) describes the continuous formation of organozinc halides using the rarely used, yet powerful, Negishi cross coupling bond forming reaction. 

²The Group of Prof Steven V. Ley, Department of Chemistry (University of Cambridge, UK) has outlined a possible breakthrough for the manufacture of breast cancer drug Tamoxifen using an advanced peristaltic pumping system that enables the processing of organometallic reagents. The paper also describes a range of organometallic reactions that can run continuously using the advanced Vapourtec V-3 pumps.

³Researchers from the Ludwig-Maximilians-Universitat Munchen have shown a procedure for functionalizing a range of heterocycles and various sensitive acrylates using the strong, non-nucleotide Knochel-Hauser base TMPMgCl.LiCl and the subsequent quenching with various electrophiles. The ability of the V-3 pump to continuously process reagents of this type allows for the multi-gram scale-up of these reactions previously limited to small scale. The magnesiation of pyridines, pyrimidines, thiophenes, thiazoles and functionalized acrylates are described in excellent yields.